Reid Huber

Reid Huber has extensive experience in the biotechnology and pharmaceutical industry. Reid is currently a Partner at Third Rock Ventures since December 2018. In 2022, they joined Rapport Therapeutics as a Director. Previously, they held roles as a Director and CEO at MOMA Therapeutics from 2020 to 2021. Huber also served as a Director at Terremoto Biosciences, Tango Therapeutics, and Asher Biotherapeutics. Reid was a Board Observer at insitro and Director at Bellicum Pharmaceuticals, Inc. Additionally, Huber has served as a Director at Eastern New England Board of the American Cancer Society and Partners HealthCare, Innovation Growth Board.

Reid Huber completed their Bachelor of Science degree in Molecular Genetics/Biochemistry from Murray State University from 1991 to 1994. Reid then pursued their higher education at Washington University School of Medicine in St. Louis, where they obtained their PhD in Molecular Genetics/Biochemistry from 1994 to 1998.